NCT03776032 2018-12-20
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
Amgen
Phase 3 Completed
Clinical Trials
10 trialsNCT00135317 2013-05-23
AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies
Amgen
Phase 3 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00118638 2013-04-29
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00110955 2010-01-15
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00115167 2009-05-11
A Study of Darbepoetin Alfa in Anemic Subjects Not Receiving Chemotherapy Who Have Completed the 20010103 Study
Amgen
Phase 3 Completed
NCT00119613 2008-08-08
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
Amgen
Phase 3 Completed
NCT00111137 2008-02-28
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Amgen
Phase 3 Completed
NCT00117624 2007-12-28
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
Amgen
Phase 3 Completed